2G,H), indicating that Ex-4's effect is mediated through GLP-1R
Vis-a-vis, the FDA and the CV discussions, we are essentially have had very constructive dialog with the agency, where basically they are confirming that we have promising data with the SUSTAIN 6, however they need some kind of confirmation before we can have a CV indication for Ozempic and that confirmation can actually come in the form of either a bridging study even with an oral route of administration of semaglutide such as the so-called oral trial
Most providers recommend switching at the beginning of your next scheduled dose
Animal studies show no fetal harm at therapeutic semaglutide doses, but human pregnancy data is limited, placing it in is not recommended during pregnancy
Importantly, the use of semaglutide 2.4 mg for weight management has a favorable safety profile
These products are not interchangeable with GLP-1 medications or diabetes treatment, and taking all four together may create unnecessary strain overlap